Syndax Pharmaceuticals (SNDX) Interest Expenses (2020 - 2026)

Syndax Pharmaceuticals' Interest Expenses history runs 12 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 47.5% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $3.9 million (down 69.87% YoY), while the FY2025 annual figure was $56.9 million, down 78.01% from the prior year.
• Interest Expenses for Q1 2026 stood at $11.8 million, up from -$24.2 million in the prior quarter.
• The five-year high for Interest Expenses was $11.8 million in Q1 2026, with the low at -$24.2 million in Q4 2025.
• The 5-year median for Interest Expenses is $756000.0 (2024), against an average of $1.3 million.
• Peak annual rise in Interest Expenses reached 35986.96% in 2025, while the deepest fall reached 596.08% in 2025.
• Syndax Pharmaceuticals' Interest Expenses stood at $41000.0 in 2022, then jumped by 53.66% to $63000.0 in 2023, then jumped by 7641.27% to $4.9 million in 2024, then slumped by 596.08% to -$24.2 million in 2025, then surged by 148.77% to $11.8 million in 2026.
• Business Quant data shows SNDX's Interest Expenses at $11.8 million in Q1 2026, -$24.2 million in Q4 2025, and $8.3 million in Q3 2025.